Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-26, Stock:LLY, The news for the past five days is as follows:
2019-02-19: NEWS1: Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018.NEWS2: Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why.NEWS3: Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why.NEWS4: Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo.NEWS5: Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo.NEWS6: What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?.NEWS7: Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo.NEWS8: Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why.NEWS9: Pfizer-Lilly drug shown to help reduce back pain in late-stage trial.NEWS10: Higher dose of Pfizer-Lilly drug helps reduce back pain in study.NEWS11: Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain.
2019-02-20: NEWS1: Better Buy: Pfizer vs. Eli Lilly.NEWS2: Better Buy: Pfizer vs. Eli Lilly.NEWS3: Better Buy: Pfizer vs. Eli Lilly.NEWS4: Notable Wednesday Option Activity: LLY, DVN, IRM.NEWS5: Notable Wednesday Option Activity: LLY, DVN, IRM.NEWS6: Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study.NEWS7: Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study.NEWS8: Allergan Responds to Investor's Call for CEO/Chair Role Split.NEWS9: Allergan Responds to Investor's Call for CEO/Chair Role Split.NEWS10: Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's notes; stable outlook.NEWS11: Allergan Responds to Investor's Call for CEO/Chair Role Split.NEWS12: Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study.
2019-02-21: NEWS1: IVW, NFLX, LLY, PYPL: ETF Outflow Alert.NEWS2: IVW, NFLX, LLY, PYPL: ETF Outflow Alert.NEWS3: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS4: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS5: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.
2019-02-22: NEWS1: Merck to Buy Immunotherapy Developer Immune Design for $300M.NEWS2: U.S. Senators launch bipartisan probe into rising insulin prices.NEWS3: ELAN or ZTS: Who Is Expected to Report Faster EPS Growth?.NEWS4: Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates.NEWS5: Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates.NEWS6: Is Eli Lilly and Company’s (NYSE:LLY) Balance Sheet Strong Enough To Weather A Storm?.NEWS7: Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review.NEWS8: Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review.NEWS9: Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates.NEWS10: Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review.NEWS11: New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, Changyou, J.B. Hunt Transport Services, and Eli Lilly — Consolidated Revenues, Company Growth, and Expectations for 2019.NEWS12: What Pharma Investors Need to Know About Pfizer's Latest Disaster.NEWS13: What Pharma Investors Need to Know About Pfizer's Latest Disaster.NEWS14: What Pharma Investors Need to Know About Pfizer&apos;s Latest Disaster.
2019-02-25: NEWS1: The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft.NEWS2: The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft.NEWS3: Better Buy: Eli Lilly vs. Johnson & Johnson.NEWS4: Better Buy: Eli Lilly vs. Johnson & Johnson.NEWS5: The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft.NEWS6: Better Buy: Eli Lilly vs. Johnson & Johnson.

Answer: Rise